ESCITALOPRAM WITHDRAWAL SYMPTOMS /
DISCONTINUING ESCITALOPRAM NATURALLY
Have you tried discontinuing Escitalopram and suffered Escitalopram withdrawal symptoms? The antidepressant withdrawal syndrome is why many reinstate the Escitalopram or seek help to diminish the Escitalopram withdrawal symptoms. Discontinuing Escitalopram must be done gradually, yet many find the symptoms interfere with all aspects of life. Additionally, the alterations to the Serotonin receptors take time to heal, and Serotonin is located throughout the human body which explains why Escitalopram withdrawal symptoms are also widespread.  If done correctly, Escitalopram withdrawal does not have to interfere with your daily life. Contact our nonprofit for help today.*
Below is information about Escitalopram, Escitalopram withdrawal, and getting off Escitalopram naturally.
I just want to say thank you to all of you for helping me at the very worst time of my life
Escitalopram Withdrawal Success
WHAT IS ESCITALOPRAM WITHDRAWAL LIKE?
I sincerely hope that my appreciation and gratefulness, and that of other customers, makes your sacrifices and long hours to make this all possible, worth the effort.by Dennis (USA) Escitalopram Withdrawal Success
ESCITALOPRAM WITHDRAWAL - DISCONTINUING ESCITALOPRAM NATURALLY
The Point of Return Escitalopram weaning at-home program is a slow taper that allows you to step down from Escitalopram under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief - you will not begin discontinuing Escitalopram until you feel ready. This is where our Advanced Nutraceuticals are critical, we know the demands placed on the body during Escitalopram withdrawal. Point of Return provides healthy, Drug-Free strategies to help ease Escitalopram withdrawal symptoms and support your well-being.*
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our innovative approach to antidepressant tapering encompasses a holistic method to empower you on your path to recovery. Don't wean Escitalopram alone, work with our Prescription Drug Experts.*
ESCITALOPRAM WITHDRAWAL SYMPTOMS MAY INCLUDE*
- balance issues
- blurred vision
- brain zaps
- concentration impairment
- crying spells
- electric shock sensations
- flu-like symptoms
- highly emotional
- impaired speech
- jumpy nerves
- lack of coordination
- headaches / increased headaches
- over-reacting to situations
- repetitive thoughts or songs
- sensory & sleep disturbances
- severe internal restlessness (akathisia)
- stomach cramps
- tinnitus (ear ringing or buzzing)
- tingling sensations
- troubling thoughts
- visual hallucinations / illusions
- vivid dreams speech or
- visual changes
- worsened depression 
I will forever be grateful for your help, and I continue to tell others about your marvelous program of drug recovery when the opportunity presents itself. I will never forget you and your compassion toward me and so many others.by Tom Escitalopram Withdrawal Success
IMAGINE BEING FREE OF ESCITALOPRAM DEPENDENCY
✔ Proven Program completed At-Home
✔ Slowly Wean Off Escitalopram
✔ All-Natural Nutraceuticals to help ease symptoms and make Escitalopram Withdrawal more comfortable*
✔ Professional information and support to empower you
✔ Free Mentoring on our 24/7 private Discussion Board
Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program (USA & Canada Only)
ESCITALOPRAM WITHDRAWAL TIMELINE
Escitalopram has a half-life (when the drug is half out of the body) of 27-32 hours, so many patients may not feel the initial reduction for 1-2 days. Symptoms from discontinuing Escitalopram are generally felt when 90% or more of the Escitalopram has left your system. However, metabolization of drugs can vary significantly and this explains why even a small reduction is felt by many. For normal metabolization approximately 6 days is required for 99% of the Escitalopram to leave your system.   Withdrawals can begin mild and continue to increase and may include digestive issues, sleep changes, trouble balancing properly, numbness, tingling, unwanted feelings of guilt, anxiety or depression. It is the widespread Escitalopram Withdrawal symptoms that drives many to start out at-home program. We know how to minimize the Escitalopram withdrawals and have a proven method used for 17 years. Contact us for help.*
I am so grateful for Point of Return and for all the support I have received to help me to taper from my antidepressant, which I had been on for about 14 years. The almost immediate replies to emails and arrival of orders was humbling and the wonderful support of the POR team was a great help to me throughout the whole process. I found the slow-tapering programme to be both sensible and doable and have learned so much from undertaking the programme. Thank you so much to all at Point of Return. May God bless you!
BY LOUISE (IRELAND)
Antidepressant Withdrawal Success
ESCITALOPRAM WITHDRAWAL SUCCESS STORIES
I hope that anyone who is seeking to change their life by stopping these medications finds Point of Return. Thank you! More...
Denise (Escitalopram Withdrawal Success Story)
I just want to say thank you to all of you for helping me at the very worst time of my life. I can't tell you enough how much I appreciate Point of Return. I will refer anyone I know. More...
Bob (Escitalopram Withdrawal Success Story)
I will forever be grateful for your help and will continue to tell others about your marvelous withdrawal program of prescription drug recover when the opportunity presents itself. More...
Tom (Escitalopram Withdrawal Success Story)
Thank you from the bottom of my heart. Your team members, each one of you, are truly life-savers!!! More...
Dennis (Escitalopram Withdrawal Success Story)
Prayers of thanks for the Point of Return's staff will forever be on my lips! More...
Karen (Escitalopram Withdrawal Success Story)
N.L. (Escitalopram Withdrawal Success Story)
ESCITALOPRAM SIDE EFFECTS AND ADVERSE REACTIONS
ESCITALOPRAM SIDE EFFECTS MAY INCLUDE:
Constipation, decreased appetite, decreased sex drive, diarrhea, dizziness, dry mouth, ejaculation disorder, fatigue, flu-like symptoms, impotence, indigestion, insomnia, nausea, runny nose, sinusitis, sleepiness, sweating, abdominal pain, abnormal dreaming, allergic reactions, blurred vision, bronchitis, chest pain, coughing, earache, fever, gas, heartburn, high blood pressure, hot flushes, increased appetite, irritability, joint pain, lack of concentration, lack of energy, lack of orgasm, light-headedness, menstrual cramps, migraine, muscle pain, nasal congestion, neck and shoulder pain, pain in arms or legs, palpitations, rash, ringing in the ears, sinus congestion, sinus headache, stomachache, tingling, toothache, tremors, urinary problems, vertigo, vomiting, weight changes, yawning*
ESCITALOPRAM ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: pancreatitis, tardive dyskinesia, seizures, suicidal ideation, SIADH, hemolytic anemia, agranulocytosis, GI bleeding, aplastic anemia, heart failure, bradycardia, hypertensive crisis, torsade de pointes, thrombosis, atrial fibrillation, stroke, myocardial infarction, ventricular tachycardia, anaphylactoid reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS, erythema multiforme, angioedema, toxic epidermal necrolysis, Stevens-Johnson syndrome, pulmonary embolism , visual impairment, ocular hypertension, hepatic failure, hepatic necrosis, spontaneous fetal abortion, renal failure (unspecified), rhabdomyolysis, serotonin syndrome, bone fractures, persistent pulmonary hypertension of the newborn, neonatal abstinence syndrome*
Moderate: ejaculation dysfunction, constipation, impotence (erectile dysfunction), dysphagia , akathisia, choreoathetosis, pseudoparkinsonism, dysarthria, ataxia, migraine, myoclonia, dystonic reaction, nystagmus, amnesia, confusion, delirium, nmania, psychosis, hostilit, impulse control symptoms, hallucinations, depression, hyponatremia, platelet dysfunction, hypoprothrombinemia , anemia, thrombocytopenia, bleeding, leukopenia, hematoma, hypertension, peripheral vasodilation, chest pain (unspecified), phlebitis, QT prolongation, hypotension, orthostatic hypotension, sinus tachycardia, palpitations, edema, dyspnea, blurred vision, hyperbilirubinemia, hepatitis, elevated hepatic enzymes, hyperprolactinemia, priapism, urinary retention, dysuria, myasthenia, hyperglycemia, diabetes mellitus, hypoglycemia, hypokalemia, hypercholesterolemia, osteopenia, withdrawal ,growth inhibition*
Mild: headache, nausea, drowsiness, insomnia, xerostomia, diarrhea, fatigue, libido decrease, hyperhidrosis, dizziness, rhinitis, dyspepsia, vomiting, lethargy, sinusitis, orgasm dysfunction, dental pain, abdominal pain, paresthesias, yawning, menstrual irregularity, flatulence, weight loss, pyrosis (heartburn), gastroesophageal reflux, hypoesthesia, asthenia, nightmare, tremor, vertigo, restless legs syndrome (RLS), emotional lability, irritability, restlessness, agitation, paranoia, anxiety, purpura, epistaxis, ecchymosis, syncope, malaise, fever, rash, photosensitivity, flushing, urticaria, alopecia, cough, nasal congestion, diplopia, mydriasis, tinnitus, dysmenorrhea, menorrhagia, increased urinary frequency, muscle cramps, arthralgia, myalgia, back pain*
ESCITALOPRAM BOXED WARNINGS: per PDR:
Children, growth inhibition, suicidal ideation
Safety and efficacy have not been established in pediatric populations for any indication except for the treatment of major depressive disorder in children and adolescents 12 years of age and older. There is a causal relationship between the use of antidepressants, such as escitalopram, and the risk of suicidal ideation and behavior in children, adolescents, and young adults (ages 18 to 24 years). The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants (SSRIs and others). The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with SSRIs and other antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in children or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or at the time of dose increase or decrease. It is unknown if the suicidality risk in children and young adults extends to longer-term therapy (i.e., beyond several months). The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder such as obsessive-compulsive disorder (OCD). All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment are considered at an increased risk for suicidal ideation or attempts, and should be closely monitored during treatment with escitalopram. In patients who exhibit changes in symptoms, worsening of depression or emergent suicidality, a decision should be made to change or discontinue treatment. If discontinuing, medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose. The potential for growth inhibition in pediatric patients should be monitored during SSRI therapy. Monitor height and weight periodically while the patient is receiving escitalopram. Data are inadequate to determine whether the chronic use of SSRIs causes long-term growth inhibition; however, decreased weight gain has been observed in children and adolescents receiving escitalopram.*
ESCITALOPRAM TECHNICAL DATA AND REFERENCES
According to the FDA regarding the discontinuation of Escitalopram, marketed as Lexapro and Cipralex: Discontinuing Lexapro: A gradual dose reduction is recommended (2.4). Discontinuation of Treatment with Lexapro: A gradual reduction in dose rather than abrupt cessation is recommended whenever possible (5.3). 2.4 Discontinuation of Treatment with Lexapro Symptoms associated with discontinuation of Lexapro and other SSRIs and SNRIs have been reported [see Warnings and Precautions (5.3)]. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.*
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with Your physician to help you with your drug withdrawal process and with his or her consent throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..